Amedisys Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Amedisys wird ein jährliches Gewinn- und Umsatzwachstum von 62.1% bzw. 4.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 67.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.6% betragen.

Wichtige Informationen

62.1%

Wachstumsrate der Gewinne

67.1%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	28.7%
Wachstumsrate der Einnahmen	4.3%
Zukünftige Eigenkapitalrendite	12.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Sep 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:AMED * - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	2,499	156	225	N/A	6
12/31/2024	2,340	149	191	190	13
12/31/2023	2,241	34	201	155	10
6/30/2023	2,229	2	101	114	N/A
3/31/2023	2,234	112	103	111	N/A
12/31/2022	2,223	119	126	133	N/A
9/30/2022	2,220	121	91	98	N/A
6/30/2022	2,216	140	166	173	N/A
3/31/2022	2,222	191	177	184	N/A
12/31/2021	2,214	209	182	189	N/A
9/30/2021	2,206	220	242	250	N/A
6/30/2021	2,196	247	264	271	N/A
3/31/2021	2,117	202	331	337	N/A
12/31/2020	2,072	184	284	289	N/A
9/30/2020	2,021	166	294	298	N/A
6/30/2020	1,972	128	256	263	N/A
3/31/2020	1,980	127	180	188	N/A
12/31/2019	1,956	127	194	202	N/A
9/30/2019	1,889	127	184	191	N/A
6/30/2019	1,812	124	204	212	N/A
3/31/2019	1,731	123	197	203	N/A
12/31/2018	1,663	119	217	223	N/A
9/30/2018	1,626	88	184	192	N/A
6/30/2018	1,583	71	128	133	N/A
3/31/2018	1,546	42	111	119	N/A
12/31/2017	1,511	30	95	106	N/A
9/30/2017	1,474	43	91	102	N/A
6/30/2017	1,456	40	85	99	N/A
3/31/2017	1,438	46	N/A	77	N/A
12/31/2016	1,419	37	N/A	62	N/A
9/30/2016	1,391	41	N/A	54	N/A
6/30/2016	1,358	38	N/A	78	N/A
3/31/2016	1,313	38	N/A	106	N/A
12/31/2015	1,266	-3	N/A	108	N/A
9/30/2015	1,230	-7	N/A	92	N/A
6/30/2015	1,204	-7	N/A	87	N/A
3/31/2015	1,193	-10	N/A	-45	N/A
12/31/2014	1,188	13	N/A	-66	N/A
9/30/2014	1,191	-4	N/A	-62	N/A
6/30/2014	1,192	-103	N/A	-59	N/A
3/31/2014	1,203	-109	N/A	64	N/A
12/31/2013	1,233	-93	N/A	102	N/A
9/30/2013	1,278	-191	N/A	109	N/A
6/30/2013	1,340	-90	N/A	103	N/A
3/31/2013	1,394	-84	N/A	91	N/A
12/31/2012	1,420	-80	N/A	69	N/A
9/30/2012	1,441	33	N/A	91	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AMED *Das prognostizierte Gewinnwachstum (62.1% pro Jahr) liegt über der Sparquote (7.6%).

Ertrag vs. Markt: AMED *Die Erträge des Unternehmens (62.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MX (11.2% pro Jahr).

Hohe Wachstumserträge: AMED *Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: AMED *Die Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt MX (7.1% pro Jahr).

Hohe Wachstumseinnahmen: AMED *Die Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AMED *Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.6 %).

Amedisys Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

Recent updates

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

High number of new directors

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

High number of new directors

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

High number of new directors

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

High number of new directors

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$3.0m worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Investor sentiment improved over the past week

High number of new directors

High number of new directors

Independent Director recently sold Mex$42m worth of stock

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

Investor sentiment deteriorated over the past week

High number of new directors

President & COO recently sold Mex$1.5m worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold Mex$10m worth of stock

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

Independent Director recently bought Mex$5.3m worth of stock

Revenue misses expectations

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Defensive Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken